To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of an advanced solid tumor that is not responding to standard therapy or for which no standard therapy exists.
- At least 3 weeks must have passed since completion of prior therapies and entry into the study, and patients must have recovered from any serious side effects.
- Patients with iron or copper overload syndromes (such as hemochromatosis or Wilson’s disease) may not participate.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Andrea Cercek at 646-888-4189.